Tags

Type your tag names separated by a space and hit enter

Montelukast in guidelines and beyond.
Adv Ther. 2009 Jun; 26(6):575-87.AT

Abstract

In all asthma guidelines, preventive anti-inflammatory treatment is essential in all patients with persistent asthma. Inhaled corticosteroids are the mainstay of treatment in the control of asthma, but other treatments may be used as a monotherapy in patients with mild asthma or as an add-on treatment in those with moderate-to-severe asthma. Leukotriene modifiers are the only validated preventive treatment for all age groups. This review discusses the place of montelukast, a leukotriene receptor antagonist, using guidelines and consensus reports on asthma and rhinitis: the US National Asthma Education and Prevention Program (NAEPP); the British Guideline on the Management of Asthma; the Global Initiative on Asthma (GINA); and Allergic Rhinitis and its Impact on Asthma (ARIA). This review includes new studies that have not yet been considered in guidelines.

Authors+Show Affiliations

Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, 371 avenue Doyen Gaston Giraud, 34275 Montpellier, Cedex 5, France. jean.bousquet@inserm.frNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19562275

Citation

Bousquet, Jean, et al. "Montelukast in Guidelines and Beyond." Advances in Therapy, vol. 26, no. 6, 2009, pp. 575-87.
Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv Ther. 2009;26(6):575-87.
Bousquet, J., Demoly, P., & Humbert, M. (2009). Montelukast in guidelines and beyond. Advances in Therapy, 26(6), 575-87. https://doi.org/10.1007/s12325-009-0038-1
Bousquet J, Demoly P, Humbert M. Montelukast in Guidelines and Beyond. Adv Ther. 2009;26(6):575-87. PubMed PMID: 19562275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Montelukast in guidelines and beyond. AU - Bousquet,Jean, AU - Demoly,Pascal, AU - Humbert,Marc, Y1 - 2009/06/26/ PY - 2009/03/02/received PY - 2009/6/30/entrez PY - 2009/6/30/pubmed PY - 2009/12/16/medline SP - 575 EP - 87 JF - Advances in therapy JO - Adv Ther VL - 26 IS - 6 N2 - In all asthma guidelines, preventive anti-inflammatory treatment is essential in all patients with persistent asthma. Inhaled corticosteroids are the mainstay of treatment in the control of asthma, but other treatments may be used as a monotherapy in patients with mild asthma or as an add-on treatment in those with moderate-to-severe asthma. Leukotriene modifiers are the only validated preventive treatment for all age groups. This review discusses the place of montelukast, a leukotriene receptor antagonist, using guidelines and consensus reports on asthma and rhinitis: the US National Asthma Education and Prevention Program (NAEPP); the British Guideline on the Management of Asthma; the Global Initiative on Asthma (GINA); and Allergic Rhinitis and its Impact on Asthma (ARIA). This review includes new studies that have not yet been considered in guidelines. SN - 0741-238X UR - https://www.unboundmedicine.com/medline/citation/19562275/Montelukast_in_guidelines_and_beyond_ L2 - https://dx.doi.org/10.1007/s12325-009-0038-1 DB - PRIME DP - Unbound Medicine ER -